Cargando…

Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors

BACKGROUND: Mutation analysis of KIT and PDGFRA genes in gastrointestinal stromal tumors is gaining increasing importance for prognosis of GISTs and for prediction of treatment response. Several groups have identified specific mutational subtypes in KIT exon 11 associated with an increased risk of m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merkelbach-Bruse, Sabine, Dietmaier, Wolfgang, Füzesi, Laszlo, Gaumann, Andreas, Haller, Florian, Kitz, Julia, Krohn, Antje, Mechtersheimer, Gunhild, Penzel, Roland, Schildhaus, Hans-Ulrich, Schneider-Stock, Regine, Simon, Ronald, Wardelmann, Eva
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Technical Advance
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910708/ https://www.ncbi.nlm.nih.gov/pubmed/20598160 http://dx.doi.org/10.1186/1471-2350-11-106

Ejemplares similares

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors
por: Gao, Jing, et al.
Publicado: (2016)

Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue
por: FASSUNKE, JANA, et al.
Publicado: (2015)

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro
por: Künstlinger, Helen, et al.
Publicado: (2015)

A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del)
por: Huss, Sebastian, et al.
Publicado: (2013)

Small Cell Carcinoma of the Urinary Bladder: KIT and PDGFRA Gene Mutations
por: Eliyakin, Nuket, et al.
Publicado: (2015)

KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors
por: Palomba, Grazia, et al.
Publicado: (2020)

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
por: Joensuu, Heikki, et al.
Publicado: (2023)

qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL
por: Fassunke, Jana, et al.
Publicado: (2010)

Mutational Analysis of c-KIT and PDGFRA in Canine Gastrointestinal Stromal Tumors (GISTs)
por: Morini, Maria, et al.
Publicado: (2022)

TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities
por: Koelsche, Christian, et al.
Publicado: (2014)

The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting
por: Maleddu, Alessandra, et al.
Publicado: (2011)

Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis
por: Zong, Liang, et al.
Publicado: (2014)

Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors
por: Rossi, Sabrina, et al.
Publicado: (2016)

PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1
por: Baskin, Yasemin, et al.
Publicado: (2016)

Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST
por: Astolfi, Annalisa, et al.
Publicado: (2020)

Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations
por: Rizzo, Francesca Maria, et al.
Publicado: (2016)

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
por: Ip, Carman K. M., et al.
Publicado: (2018)

Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment
por: Ihle, Michaela Angelika, et al.
Publicado: (2018)

Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient
por: Negri, T, et al.
Publicado: (2007)

Chromosome copy number changes carry prognostic information independent of KIT/PDGFRA point mutations in gastrointestinal stromal tumors
por: Silva, Mara, et al.
Publicado: (2010)

Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy
por: Heydt, Carina, et al.
Publicado: (2015)

Data on quantification of signaling pathways activated by KIT and PDGFRA mutants
por: Bahlawane, Christelle, et al.
Publicado: (2016)

Morphological Correlates of KIT and PDGFRA Genotypes in Gastrointestinal Stromal Tumour
por: Priya, Valli, et al.
Publicado: (2020)

Succinate dehydrogenase deficiency in a PDGFRA mutated GIST
por: Belinsky, Martin G., et al.
Publicado: (2017)

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma
por: Lassus, H, et al.
Publicado: (2004)

Malignant melanoma of the conjunctiva: a case report with examination of KIT and PDGFRA
por: Terada, Tadashi
Publicado: (2012)

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019)

PDGFRA, KIT, and KDR Gene Amplification in Glioblastoma: Heterogeneity and Clinical Significance
por: Carlotto, Bianca Soares, et al.
Publicado: (2023)

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
por: Bauer, Sebastian, et al.
Publicado: (2021)

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
por: Grellety, Thomas, et al.
Publicado: (2015)

An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors
por: Sun, Yingchao, et al.
Publicado: (2022)

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
por: Reichardt, Peter, et al.
Publicado: (2016)

Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit
por: Bando, Hideaki, et al.
Publicado: (2013)

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations
por: Ihle, Michaela Angelika, et al.
Publicado: (2014)

Metanephric stromal tumor in an adult with PDGFRA mutation: a case report
por: Guo, Sanjun, et al.
Publicado: (2023)

MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas
por: Schmitz, Katja, et al.
Publicado: (2015)

Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors
por: Pantaleo, Maria A, et al.
Publicado: (2014)

The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients – Design of the Urodiag® PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC)
por: Roperch, Jean-Pierre, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_74i1ev1o37gigoip99durc4k3o